Berisha-Muharremi Venera, Tahirbegolli Bernard, Phypers Ruth, Hanna Reem
Faculty of Medicine, University of Prishtina, Bulevardi i Dëshmorëve nn, 10000 Prishtina, Kosovo.
Poliklinika Endomedica, Muharrem Fejza Str. Nr. 84, 10000 Prishtina, Kosovo.
Biomedicines. 2025 Jun 25;13(7):1555. doi: 10.3390/biomedicines13071555.
: Hashimoto thyroiditis (HT) is an autoimmune disease affecting the thyroid, often leading to hypothyroidism, even in individuals with adequate iodine intake. Despite achieving biochemical euthyroidism through levothyroxine (LT4) therapy, many patients continue to experience persistent symptoms, likely due to ongoing thyroid autoimmunity. Photobiomodulation (PBM) has shown promise in treating autoimmune conditions, but its effect on thyroid volume (TV) remains unclear. This study aimed to assess the efficacy of PBM combined with supplements in restoring thyroid function and normalising TV compared to the use of supplements alone. Ninety-eight females aged 20-50 years old were divided into two groups: Group 1 received PBM and supplements and Group 2 received supplements only. The PBM parameters were as follows: 820 nm wavelength, 200 mW power, continuous mode, 20 s per point at 8 points (32 J/cm per point), twice weekly for three weeks. Both groups received vitamin D3 supplementation (if serum < 40 ng/dL) and 100 µg of oral selenium daily. Ninety-seven participants completed the study (51 in Group 1, 46 in Group 2). Group 1 showed significantly greater improvements in TV normalisation and weight loss and reductions in BMI, waist/hip circumference, waist-to-hip ratio, TSH, anti-TPO, anti-TG, and LT4 dosage ( < 0.05). This study demonstrates that low-fluence PBM combined with supplements can effectively improve thyroid function, reduce TV, and enhance anthropometric and clinical outcomes in HT patients. The protocol holds potential for broader application and further validation in larger trials.
桥本甲状腺炎（HT）是一种影响甲状腺的自身免疫性疾病，即使在碘摄入充足的个体中也常导致甲状腺功能减退。尽管通过左甲状腺素（LT4）治疗实现了生化甲状腺功能正常，但许多患者仍持续出现症状，这可能是由于甲状腺自身免疫持续存在。光生物调节（PBM）在治疗自身免疫性疾病方面显示出前景，但其对甲状腺体积（TV）的影响仍不清楚。本研究旨在评估与单独使用补充剂相比，PBM联合补充剂在恢复甲状腺功能和使TV正常化方面的疗效。98名年龄在20至50岁之间的女性被分为两组：第1组接受PBM和补充剂，第2组仅接受补充剂。PBM参数如下：波长820nm，功率200mW，连续模式，每点20秒，共8点（每点32J/cm），每周两次，共三周。两组均接受维生素D3补充剂（如果血清<40ng/dL），每天口服100μg硒。97名参与者完成了研究（第1组51名，第2组46名）。第1组在TV正常化、体重减轻以及BMI、腰臀围、腰臀比、促甲状腺激素（TSH）、抗甲状腺过氧化物酶（anti-TPO）、抗甲状腺球蛋白（anti-TG）和LT4剂量降低方面显示出显著更大的改善（P<0.05）。本研究表明，低剂量PBM联合补充剂可有效改善HT患者的甲状腺功能，减少TV，并改善人体测量和临床结果。该方案在更大规模试验中具有更广泛应用和进一步验证的潜力。
